Mostrando 3 resultados de: 3
Identifying pbkp_redictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients
ArticleAbstract: Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately asPalabras claves:Causal inference, CIMAvaxEGF, Non-small-cell lung cancer, Pbkp_redictive biomarkersAutores:Alonso A., Lage Davila A., Luaces P.L.o., Molenberghs G., Saavedra Hernández D., Sánchez L., Tania Crombet, Van der Elst W.Fuentes:scopusIs there a subgroup of long-term evolution among patients with advanced lung cancer?: Hints from the analysis of survival curves from cancer registry data
ArticleAbstract: Background: Recently, with the access of low toxicity biological and targeted therapies, evidence ofPalabras claves:Long-term survivors, Mixture models, Non-small-cell lung cancer, SurvivalAutores:Ballesteros J., Carmen Elena Viada, Galán Y.H., Lage Davila A., Luaces P.L.o., Sánchez L., Tania CrombetFuentes:scopusThymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
ArticleAbstract: Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy rPalabras claves:Biomodulina T, CIMAvax-EGF, naïve T cells, Non-small-cell lung cancer, PD-1, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Díaz M., González A., Hernández J.d.l.C., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Molina M.d.l.A., Peña Y., Pereira K., Portela S., Ramos R., Reyes M.C., Saavedra Hernández D., Suárez G.M., Tania CrombetFuentes:scopus